[go: up one dir, main page]

HK1254190A1 - 通用供體幹細胞和相關方法 - Google Patents

通用供體幹細胞和相關方法

Info

Publication number
HK1254190A1
HK1254190A1 HK18113328.6A HK18113328A HK1254190A1 HK 1254190 A1 HK1254190 A1 HK 1254190A1 HK 18113328 A HK18113328 A HK 18113328A HK 1254190 A1 HK1254190 A1 HK 1254190A1
Authority
HK
Hong Kong
Prior art keywords
stem cells
related methods
universal donor
donor stem
universal
Prior art date
Application number
HK18113328.6A
Other languages
English (en)
Inventor
b meissner Torsten
M R Ferreira Leonardo
L Strominger Jack
A Cowan Chad
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of HK1254190A1 publication Critical patent/HK1254190A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
HK18113328.6A 2015-05-08 2018-10-18 通用供體幹細胞和相關方法 HK1254190A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158999P 2015-05-08 2015-05-08
PCT/US2016/031551 WO2016183041A2 (en) 2015-05-08 2016-05-09 Universal donor stem cells and related methods

Publications (1)

Publication Number Publication Date
HK1254190A1 true HK1254190A1 (zh) 2019-07-12

Family

ID=57249476

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113328.6A HK1254190A1 (zh) 2015-05-08 2018-10-18 通用供體幹細胞和相關方法

Country Status (8)

Country Link
US (9) US10968426B2 (zh)
EP (1) EP3294342A4 (zh)
JP (3) JP2018515139A (zh)
CN (1) CN107921148A (zh)
AU (3) AU2016261600B2 (zh)
CA (1) CA2988854A1 (zh)
HK (1) HK1254190A1 (zh)
WO (1) WO2016183041A2 (zh)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
CN116059378A (zh) * 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CN107208055B (zh) * 2015-01-17 2021-06-15 浙江大学 引起免疫原性反应降低的被修饰细胞
AU2016261600B2 (en) 2015-05-08 2021-09-23 President And Fellows Of Harvard College Universal donor stem cells and related methods
US12037583B2 (en) * 2015-12-04 2024-07-16 Novartis Ag Compositions and methods for immunooncology
KR102032354B1 (ko) * 2016-11-11 2019-10-16 가톨릭대학교 산학협력단 신규한 배양보조세포 및 이를 이용한 감마 델타 ｔ 세포의 증식 방법
GB201619876D0 (en) 2016-11-24 2017-01-11 Cambridge Entpr Ltd Controllable transcription
WO2018101796A1 (ko) * 2016-12-02 2018-06-07 가톨릭대학교 산학협력단 멀티플렉스 ＣＲＩＳＰＲ-Ｃａｓ９ 시스템을 이용한 ＨＬＡ 결핍 세포주로부터 제조된 인공항원제시세포 및 이의 용도
CN107760680B (zh) * 2016-12-28 2020-09-22 北京微旋基因技术有限公司 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
WO2018132783A1 (en) * 2017-01-13 2018-07-19 The Regents Of The University Of California Immunoengineered pluripotent cells
CN119120363A (zh) * 2017-03-20 2024-12-13 华盛顿大学 细胞及其使用和制备方法
BR112019018124A2 (pt) 2017-03-22 2020-04-07 Intellia Therapeutics Inc composições e métodos para imunooncologia
US10934336B2 (en) * 2017-04-13 2021-03-02 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN110914289B (zh) 2017-05-12 2024-05-14 克里斯珀医疗股份公司 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途
EP3638258A4 (en) 2017-06-12 2021-09-08 Sinai Health System ALLOGRAFT TOLERANCE WITHOUT REQUIRING SYSTEMIC IMMUNE SUPPRESSION
JP2020530277A (ja) 2017-06-30 2020-10-22 セレクティスＣｅｌｌｅｃｔｉｓ 反復投与のための細胞免疫療法
US20190004063A1 (en) * 2017-06-30 2019-01-03 Indiana University Research & Technology Corporation Compositions and methods for detecting sla reactivity
US10391156B2 (en) * 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
CN109456943A (zh) * 2017-09-06 2019-03-12 亘喜生物科技（上海）有限公司 通用型嵌合抗原受体t细胞制备技术
AU2018353112B2 (en) * 2017-10-19 2024-11-14 Cellectis Targeted gene integration of NK inhibitors genes for improved immune cells therapy
KR102761346B1 (ko) * 2018-02-16 2025-01-31 고쿠리츠 다이가쿠 호진 교토 다이가쿠 저항원성 세포의 제조 방법
US20210040449A1 (en) * 2018-02-16 2021-02-11 Kite Pharma, Inc. Modified pluripotent stem cells and methods of making and use
JP7575950B2 (ja) * 2018-04-27 2024-10-31 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現
KR20210005146A (ko) * 2018-04-27 2021-01-13 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 유전자 편집된 t 세포에서의 인간 foxp3의 발현
PE20210666A1 (es) 2018-05-11 2021-03-31 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer
CA3100386A1 (en) 2018-05-23 2019-11-28 National University Of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11202101094TA (en) * 2018-05-23 2021-03-30 Nat Univ Singapore Chimeric antigen receptors and gene editing of cd2 for immunotherapy of t-cell malignancies
US20210222127A1 (en) * 2018-05-30 2021-07-22 Kangstem Biotech Co., Ltd. Hla gene-deleted human induced pluripotent stem cell-derived mesenchymal stem cells and preparation method thereof
WO2019237035A1 (en) * 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
CN112639081A (zh) * 2018-07-17 2021-04-09 加利福尼亚大学董事会 从免疫工程化多能干细胞衍生的嵌合抗原受体t细胞
BR112021000637A2 (pt) * 2018-07-17 2021-04-13 The Regents Of The University Of California Célula cardíaca hipoimune isolada, método para tratar um paciente que sofre de uma afecção ou doença cardíaca, método para produzir uma população de células cardíacas hipoimunes, célula endotelial hipoimune isolada, método para tratar um paciente que sofre de uma afecção ou doença vascular, método para produzir uma população de células endoteliais hipoimunes, neurônio dopaminérgico hipoimune isolado, método para tratar um paciente que sofre de uma doença ou afecção neurodegenerativa, método para produzir uma população de neurônios dopaminérgicos hipoimunes, célula de ilhota pancreática hipoimune isolada, método para tratar um paciente que sofre de diabetes, método para produzir uma população de células de ilhota pancreática hipoimunes, célula de epitélio pigmentado da retina (rpe) hipoimune isolada, método para tratar um paciente que sofre de uma afecção ocular, e método para produzir uma população de células de epitélio pigmentado da retina (rpe) hipoimunes
CN110819592A (zh) * 2018-08-13 2020-02-21 赛元生物科技(杭州)有限公司 一种通用供体干细胞及其制备方法
US20200080107A1 (en) * 2018-09-07 2020-03-12 Crispr Therapeutics Ag Universal donor cells
WO2020057666A1 (zh) * 2018-09-21 2020-03-26 科济生物医药（上海）有限公司 表达有嵌合受体的t细胞
US11312963B2 (en) * 2018-10-18 2022-04-26 Synerk Inc. Compositions and methods for inhibiting TIGIT gene expression
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
EP3894546A4 (en) * 2018-12-16 2022-12-21 Figene, LLC THERAPEUTIC USES OF GENEDITED FIBROBLAST
CN113874027A (zh) * 2019-02-01 2021-12-31 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
KR20210128440A (ko) * 2019-02-15 2021-10-26 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 범용 공여자 줄기 세포 및 관련 방법
US20220152115A1 (en) * 2019-03-13 2022-05-19 The Broad Institute, Inc. Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof
EP3962535A1 (en) 2019-04-30 2022-03-09 CRISPR Therapeutics AG Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
US12221622B2 (en) * 2019-05-10 2025-02-11 The Regents Of The University Of California Modified pluripotent cells
JP2022540090A (ja) * 2019-07-05 2022-09-14 インテレクソン・ゲーエムベーハー 個人のｈｌａパターンの決定、予後因子としての使用、標的遺伝子、及び治療薬
WO2021004933A1 (en) 2019-07-10 2021-01-14 Kunz Helmuth Heinrich Methods for deriving autologous and hypoimmunogenic hair follicle containing sheets in vitro
US20220267737A1 (en) * 2019-07-18 2022-08-25 University Of Rochester Cell-type selective immunoprotection of cells
JP2022543112A (ja) 2019-08-01 2022-10-07 サナ バイオテクノロジー，インコーポレイテッド Ｄｕｘ４発現細胞およびそれらの使用
AU2020336302A1 (en) 2019-08-23 2022-03-03 Sana Biotechnology, Inc. CD24 expressing cells and uses thereof
EP4022091A1 (en) * 2019-08-30 2022-07-06 Janssen Biotech, Inc. B-cell maturation complex car t construct and primers
US11118195B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
AU2020340622A1 (en) 2019-09-05 2022-03-03 Crispr Therapeutics Ag Universal donor cells
WO2021108602A1 (en) * 2019-11-26 2021-06-03 Disarm Therapeutics, Inc. Methods and compositions for neuroprotection
US20230272429A1 (en) 2020-01-13 2023-08-31 Sana Biotechnology, Inc. Modification of blood type antigens
CA3165076A1 (en) 2020-01-17 2021-07-22 Ryan Clarke Safety switches for regulation of gene expression
US20230079539A1 (en) * 2020-02-10 2023-03-16 Board Of Regents, The University Of Texas System Methods for rapid cloning and expression of hla class i cells
MX2022011245A (es) 2020-03-11 2023-01-11 Bit Bio Ltd Método de generación de células hepáticas.
WO2021195426A1 (en) 2020-03-25 2021-09-30 Sana Biotechnology, Inc. Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
EP4142879A1 (en) 2020-04-27 2023-03-08 Novartis AG Methods and compositions for ocular cell therapy
CN115916962A (zh) * 2020-04-27 2023-04-04 萨那生物技术股份有限公司 低免疫原性细胞的重复给药
WO2021231712A1 (en) * 2020-05-15 2021-11-18 Rxcell Inc. Hypoimmunogenic cells and uses thereof in immune responses
GB202007698D0 (en) * 2020-05-22 2020-07-08 Univ Ulster A genetic test to predict anti-TNF drug response
EP4159846A4 (en) * 2020-05-26 2024-08-14 Healios K.K. HYPOIMMUNOGENIC CELLS
WO2022030856A1 (ko) * 2020-08-06 2022-02-10 주식회사 강스템바이오텍 앱타머를 이용한 고기능성 인공 장기 제작 방법
WO2022032282A1 (en) * 2020-08-06 2022-02-10 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Methods and reagents for microbiome analysis
US20220049226A1 (en) * 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
CN114746152A (zh) * 2020-08-23 2022-07-12 应用干细胞有限公司 Hla-f修饰的细胞和方法
US20230364146A1 (en) * 2020-09-30 2023-11-16 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
CN114517184A (zh) * 2020-10-30 2022-05-20 未来智人再生医学研究院(广州)有限公司 一种表达adipsin的多能干细胞或其衍生物及应用
CN114457027A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达Amyloidβ抗体的多能干细胞及其衍生物与应用
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
CN114717232A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
IL303473A (en) 2020-12-31 2023-08-01 Sana Biotechnology Inc Methods and compositions for modulating car-t activity
JP2024503290A (ja) 2020-12-31 2024-01-25 クリスパー セラピューティクス アクチェンゲゼルシャフト ユニバーサルドナー細胞
US20220241328A1 (en) 2021-01-11 2022-08-04 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
EP4288088A2 (en) * 2021-02-08 2023-12-13 Intellia Therapeutics, Inc. Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
CN117042794A (zh) * 2021-02-08 2023-11-10 因特利亚治疗公司 用于免疫疗法的t细胞免疫球蛋白和粘蛋白结构域3(tim3)组合物和方法
CN117098840A (zh) * 2021-02-08 2023-11-21 因特利亚治疗公司 用于免疫疗法的自然杀伤细胞受体2b4组合物和方法
US20240252642A1 (en) 2021-05-19 2024-08-01 Sana Biotechnology, Inc. Hypoimmunogenic rhd negative primary t cells
WO2022251367A1 (en) 2021-05-27 2022-12-01 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2023274385A1 (zh) * 2021-07-01 2023-01-05 宁波茂行生物医药科技有限公司 靶向her2的通用型car-t细胞及其制备方法
CA3225283A1 (en) 2021-07-14 2023-01-19 Sonja SCHREPFER Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
JP2024528981A (ja) 2021-08-04 2024-08-01 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ４標的化ウイルスベクターの使用
US20240425820A1 (en) 2021-08-11 2024-12-26 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
JP2024531234A (ja) 2021-08-11 2024-08-29 サナ バイオテクノロジー，インコーポレイテッド 同種異系細胞療法のための遺伝子改変された初代細胞
US20240358761A1 (en) 2021-08-11 2024-10-31 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
MX2024001443A (es) 2021-08-11 2024-05-15 Sana Biotechnology Inc Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas.
EP4384193A2 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
EP4388105A1 (en) * 2021-08-16 2024-06-26 Beam Therapeutics Inc. Persistent allogeneic modified immune cells and methods of use thereof
CN117940153A (zh) * 2021-08-24 2024-04-26 因特利亚治疗公司 用于基于细胞的疗法的程序性细胞死亡蛋白1(pd1)组合物和方法
EP4419117A1 (en) 2021-10-22 2024-08-28 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023109941A1 (en) * 2021-12-16 2023-06-22 Gracell Biotechnologies (Shanghai) Co., Ltd. Cell modification
CA3241438A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
EP4479084A1 (en) 2022-02-14 2024-12-25 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
AU2023220071A1 (en) * 2022-02-16 2024-08-22 President And Fellows Of Harvard College Hypoimmunogenic beta cells and methods of producing the same
AU2023220128A1 (en) 2022-02-17 2024-08-22 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
JP2025506976A (ja) * 2022-03-04 2025-03-13 ツールゲン インコーポレイテッド 低免疫原性幹細胞、幹細胞から分化または由来した低免疫原性細胞およびこの製造方法
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023178165A2 (en) * 2022-03-15 2023-09-21 The Trustees Of Columbia University In The City Of New York Conversion resistant/condition-resistant tregs and car tregs, methods of making and methods of using
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
AU2023254488A1 (en) 2022-04-15 2024-12-05 Smartcella Solutions Ab COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS
WO2024003349A1 (en) 2022-07-01 2024-01-04 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
AU2023296835A1 (en) * 2022-07-01 2025-02-13 Janssen Biotech, Inc. Materials and methods for bioengineered ipsc populations
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
GB202211117D0 (en) * 2022-07-29 2022-09-14 Replay Holdings Llc Compositions and methods for non-immunogenecity
WO2024023801A2 (en) * 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
GB202212144D0 (en) 2022-08-19 2022-10-05 Resolution Therapeutics Ltd Cells for therapy
WO2024092015A1 (en) * 2022-10-25 2024-05-02 Wisconsin Alumni Research Foundation Adhesion molecule inhibition for stem cell therapies
WO2024097314A2 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Methods and systems for determining donor cell features and formulating cell therapy products based on cell features
CN118147049A (zh) * 2022-12-07 2024-06-07 士泽生物医药（苏州）有限公司 一种表达ceacam1的通用型细胞及其制备方法
CN118207165A (zh) * 2022-12-07 2024-06-18 士泽生物医药（苏州）有限公司 一种表达stc1的通用型细胞及其制备方法
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024169917A1 (zh) * 2023-02-16 2024-08-22 士泽生物医药（苏州）有限公司 通用型细胞及其制备方法
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025003393A1 (en) 2023-06-30 2025-01-02 Novo Nordisk A/S Enhancing neuronal differentiation of neural progenitor cells
WO2025029826A1 (en) * 2023-07-31 2025-02-06 Seraxis, Inc. Modified therapeutics cells and methods relating to the same
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272082A (en) 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
DK1482042T3 (da) 1996-03-01 2009-06-15 Euroscreen Sa Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
AU6869198A (en) 1997-03-25 1998-10-20 Morphogenesis, Inc. Universal stem cells
WO1999027076A1 (en) 1997-11-25 1999-06-03 Arc Genomic Research Pluripotent embryonic stem cells and methods of obtaining them
EP2308996A1 (en) 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis
US20020012660A1 (en) 1999-03-04 2002-01-31 Alan Colman Method of preparing a somatic cells for nuclear transfer
CA2404780A1 (en) 2000-03-27 2001-10-04 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
US6875904B2 (en) 2000-09-20 2005-04-05 The Ohio State University Research Foundation Animal model for identifying agents that inhibit or enhance CTLA4 signaling
US8013143B2 (en) 2002-02-20 2011-09-06 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
WO2005017170A2 (en) 2002-06-04 2005-02-24 Michele Calos Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
CA2565762A1 (en) * 2004-05-05 2005-12-01 Novimmune S.A. Assays for the identification of modulators of mhc class ii expression
US20060024819A1 (en) 2004-07-30 2006-02-02 Finney Robert E Integration vectors
CA2619833C (en) 2005-08-26 2017-05-09 Danisco A/S Use of crispr associated genes (cas)
EP1991578A2 (en) 2006-02-17 2008-11-19 Rappaport Family Institute For Research in the Medical Sciences Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases
EP2019839B1 (en) 2006-05-25 2011-12-07 Sangamo BioSciences, Inc. Methods and compositions for gene inactivation
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
EP2089427B1 (en) 2006-11-13 2014-07-30 Sangamo BioSciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
US20080182328A1 (en) 2006-12-19 2008-07-31 The Burnham Institute Mammalian extraembryonic endoderm cells and methods of isolation
WO2008102199A1 (en) 2007-02-20 2008-08-28 Cellectis Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof
US8105831B2 (en) 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
WO2009019528A1 (en) 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
WO2010015899A2 (en) 2008-08-04 2010-02-11 Cellectis Novel method to generate meganucleases with altered characteristics
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
FR2925918A1 (fr) 2007-12-28 2009-07-03 Pasteur Institut Typage et sous-typage moleculaire de salmonella par identification des sequences nucleotidiques variables des loci crispr
WO2009089476A1 (en) 2008-01-11 2009-07-16 Kardia Therapeutics, Inc. Adult human cardiac-derived progenitor cells
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
MX2011004268A (es) 2008-10-20 2011-06-01 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion de transtiretina.
EP2362915B1 (en) 2008-11-07 2016-12-21 DuPont Nutrition Biosciences ApS Bifidobacteria crispr sequences
KR20100133319A (ko) 2009-06-11 2010-12-21 주식회사 툴젠 표적 특이적인 게놈의 재배열을 위한 표적 특이적 뉴클레아제 및 이의 용도
US20120192298A1 (en) 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
EP3594333B1 (en) 2010-02-08 2023-11-01 Sangamo Therapeutics, Inc. Engineered cleavage half-domains
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
US20130177577A1 (en) * 2010-07-12 2013-07-11 Dana-Farber Cancer Institute, Inc. Nlrc5 as a target to intervene mhc class 1-mediated immune responses
EP2630156B1 (en) 2010-10-20 2018-08-22 DuPont Nutrition Biosciences ApS Lactococcus crispr-cas sequences
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US20140134195A1 (en) 2011-04-20 2014-05-15 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
EP2737063B1 (en) 2011-07-25 2016-06-01 Sangamo BioSciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
AU2012328682B2 (en) 2011-10-27 2017-09-21 Sangamo Therapeutics, Inc. Methods and compositions for modification of the HPRT locus
SG11201402666WA (en) 2011-12-16 2014-10-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
CN104284669A (zh) 2012-02-24 2015-01-14 弗雷德哈钦森癌症研究中心 治疗血红蛋白病的组合物和方法
EP2820159B1 (en) 2012-02-29 2019-10-23 Sangamo Therapeutics, Inc. Methods and compositions for treating huntington's disease
DK2838548T5 (en) * 2012-04-17 2024-08-05 Univ Washington Through Its Center For Commercialization Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
WO2013177228A1 (en) 2012-05-22 2013-11-28 Loma Linda University Generation of integration/transgene-free stem cells
CA2874611C (en) 2012-05-25 2023-01-24 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
WO2013188037A2 (en) 2012-06-11 2013-12-19 Agilent Technologies, Inc Method of adaptor-dimer subtraction using a crispr cas6 protein
WO2014022702A2 (en) 2012-08-03 2014-02-06 The Regents Of The University Of California Methods and compositions for controlling gene expression by rna processing
AU2013308770B2 (en) 2012-08-29 2019-01-17 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
EP3763810A3 (en) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
CN110669758A (zh) 2012-10-23 2020-01-10 基因工具股份有限公司 用于切割靶dna 的组合物及其用途
JP2016500254A (ja) 2012-12-05 2016-01-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 代謝疾患の調節のための方法および組成物
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US20140189896A1 (en) 2012-12-12 2014-07-03 Feng Zhang Crispr-cas component systems, methods and compositions for sequence manipulation
SG11201504523UA (en) 2012-12-12 2015-07-30 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
ES2542015T3 (es) 2012-12-12 2015-07-29 The Broad Institute, Inc. Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias
ES2786193T3 (es) 2012-12-12 2020-10-09 Broad Inst Inc Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
CN105121641A (zh) 2012-12-17 2015-12-02 哈佛大学校长及研究员协会 Rna-引导的人类基因组工程化
EP3620534B1 (en) 2013-03-14 2021-10-13 Caribou Biosciences, Inc. Crispr-cas compositions of nucleic acid-targeting nucleic acids
WO2014153069A2 (en) 2013-03-14 2014-09-25 Children's Medical Center Corporation Compositions and methods for reprogramming hematopoietic stem cell lineages
CN104046593A (zh) * 2013-03-14 2014-09-17 浙江大学 一种低免疫原性的人细胞及其制备方法
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
WO2014152432A2 (en) 2013-03-15 2014-09-25 The General Hospital Corporation Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
WO2014151994A1 (en) 2013-03-15 2014-09-25 Kambiz Shekdar Genome editing using effector oligonucleotides for therapeutic treatment
WO2014153470A2 (en) 2013-03-21 2014-09-25 Sangamo Biosciences, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
DK2981607T3 (da) 2013-04-03 2020-11-16 Memorial Sloan Kettering Cancer Center Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller
CN115261411A (zh) 2013-04-04 2022-11-01 哈佛学院校长同事会 利用CRISPR/Cas系统的基因组编辑的治疗性用途
WO2014184744A1 (en) 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
EP2997146A4 (en) 2013-05-15 2017-04-26 Sangamo BioSciences, Inc. Methods and compositions for treatment of a genetic condition
US20140349405A1 (en) 2013-05-22 2014-11-27 Wisconsin Alumni Research Foundation Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
DK3309248T3 (da) 2013-05-29 2021-08-02 Cellectis Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system
US9267135B2 (en) 2013-06-04 2016-02-23 President And Fellows Of Harvard College RNA-guided transcriptional regulation
EP3011035B1 (en) 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
KR20240172759A (ko) 2013-06-17 2024-12-10 더 브로드 인스티튜트, 인코퍼레이티드 간의 표적화 및 치료를 위한 ＣＲＩＳＰＲ­Ｃａｓ 시스템, 벡터 및 조성물의 전달 및 용도
WO2015006498A2 (en) 2013-07-09 2015-01-15 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
WO2015057976A1 (en) * 2013-10-17 2015-04-23 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
JP6646573B2 (ja) 2013-10-17 2020-02-14 サンガモ セラピューティクス， インコーポレイテッド ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法および組成物
US20150139994A1 (en) 2013-11-12 2015-05-21 The Regents Of The University Of California Compositions and methods for preventing allogeneic immune rejection
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
WO2015113063A1 (en) 2014-01-27 2015-07-30 Georgia Tech Research Corporation Methods and systems for identifying crispr/cas off-target sites
PL3888674T3 (pl) 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
US20170175128A1 (en) 2014-04-18 2017-06-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
GB201418965D0 (zh) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
AU2015339743C1 (en) 2014-10-31 2021-04-22 The Trustees Of The University Of Pennsylvania Altering gene expression in modified T cells and uses thereof
EP3215623A4 (en) 2014-11-06 2018-09-26 President and Fellows of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
CA3197849A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN107208055B (zh) 2015-01-17 2021-06-15 浙江大学 引起免疫原性反应降低的被修饰细胞
EP4269601A3 (en) 2015-03-27 2024-01-10 President and Fellows of Harvard College Modified t cells and methods of making and using the same
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
AU2016261600B2 (en) 2015-05-08 2021-09-23 President And Fellows Of Harvard College Universal donor stem cells and related methods
WO2017044864A1 (en) 2015-09-09 2017-03-16 Revivicor, Inc Multi-transgenic pig for xenotransplantation
DK3356524T3 (da) 2015-09-30 2021-11-15 Vycellix Inc Forøget genlevering til naturlige dræberceller, hæmatopoietiske stamceller og makrofager
CN108368520B (zh) 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
US12037583B2 (en) 2015-12-04 2024-07-16 Novartis Ag Compositions and methods for immunooncology
WO2018132783A1 (en) 2017-01-13 2018-07-19 The Regents Of The University Of California Immunoengineered pluripotent cells
EP3638258A4 (en) 2017-06-12 2021-09-08 Sinai Health System ALLOGRAFT TOLERANCE WITHOUT REQUIRING SYSTEMIC IMMUNE SUPPRESSION
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods

Also Published As

Publication number Publication date
AU2021221859A9 (en) 2021-10-14
US11618881B2 (en) 2023-04-04
WO2016183041A3 (en) 2017-01-05
EP3294342A4 (en) 2018-11-07
US12110500B2 (en) 2024-10-08
US20220112459A1 (en) 2022-04-14
US20190309259A1 (en) 2019-10-10
US20240368540A1 (en) 2024-11-07
US12031155B2 (en) 2024-07-09
US20230303969A1 (en) 2023-09-28
CA2988854A1 (en) 2016-11-17
AU2016261600B2 (en) 2021-09-23
JP2022090109A (ja) 2022-06-16
US20240368539A1 (en) 2024-11-07
JP2018515139A (ja) 2018-06-14
US12031154B2 (en) 2024-07-09
AU2021221859A1 (en) 2021-09-30
US20230303968A1 (en) 2023-09-28
US20230323288A1 (en) 2023-10-12
WO2016183041A2 (en) 2016-11-17
AU2016261600A1 (en) 2018-01-04
US11492591B2 (en) 2022-11-08
JP2025023343A (ja) 2025-02-14
US10968426B2 (en) 2021-04-06
CN107921148A (zh) 2018-04-17
EP3294342A2 (en) 2018-03-21
US20240141288A1 (en) 2024-05-02
AU2024203322A1 (en) 2024-06-06
US20210261916A1 (en) 2021-08-26
AU2021221859B2 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
AU2021221859A1 (en) Universal donor stem cells and related methods
IL259586A (en) Genetically modified stem cells and their uses
IL254734A0 (en) Modified t cells and methods for their preparation and use
HK1232140A1 (zh) 微類器官以及製造和使用它們的方法
EP3334820C0 (en) EXPANDED AND INDUCED PLURIPOTENT STEM CELLS, METHODS OF MANUFACTURE AND USE
EP3102681A4 (en) Trifunctional t cell-antigen coupler and methods and uses thereof
SG11201606934SA (en) Improved reprogramming methods and cell culture platforms
ZA201605760B (en) Immobilized proteins and use thereof
PL3586821T3 (pl) Kompozycje stymulujące komórki macierzyste i sposoby
EP3107996A4 (en) Tscm cells and methods for use
IL254156A0 (en) Methods for producing neural stem cells and their use
GB201701509D0 (en) Pluripotenet stem cells
GB201416293D0 (en) Methods and preparations
GB201613078D0 (en) Stem cells and cancer
EP3288570A4 (en) Modified stem cells and uses thereof
EP3101121A4 (en) Odontogenic stem cells and use of genetically modified odontogenic stem cells
GB201408091D0 (en) Methods and uses
GB201703069D0 (en) Universal donor cells
IL250272A0 (en) Enzyme without sugar residue and its uses
SG10201403640XA (en) Stem cells
GB201418980D0 (en) Cell assay kit and method
GB201605354D0 (en) Modified enzyme
GB201412545D0 (en) Enzymatic processes and uses
AU2015904224A0 (en) Isolated stem cells and methods for use therein
AU2015904486A0 (en) Stem cell line and use thereof